Zevra Therapeutics, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$34M
↑+183.4% +$22Mvs FY2024 (Q4)
Gross Profit
$33M
↑+205.4% +$22Mvs FY2024 (Q4)
Operating Income
$9M
Net Income
$7M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $34M | $12M |
| COGS | $2M | $1M |
| Gross Profit | $33M | $11M |
| R&D | $3M | $8M |
| SG&A | $20M | $16M |
| D&A | $362K | $2M |
| Other OpEx | $0 | $0 |
| Operating Income | $9M | $0 |
| Interest Exp. | $2M | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $7M | $0 |
| Tax | $501K | $0 |
| Net Income | $7M | $0 |
QuarterCharts · SEC EDGAR data · ZVRA · Comparing FY2025 (Q4) vs FY2024 (Q4)